Menu

Blog

In Case You Missed It: Week of Oct. 10, 2014

Posted on Fri, Oct 10, 2014
In Case You Missed It: Week of Oct. 10, 2014

“In Case You Missed It” is a weekly roundup of popular healthcare headlines. 

[OPINION] The Ebola Outbreak: Don’t Blame the Nurse.
There is a lot of talk about why the man diagnosed with Ebola at Texas Health Presbyterian Hospital … >>

Is the Quantified Employee a Healthier Employee? Wearable fitness trackers are seen as a way for companies to ensure employees are keeping active, but are they fit for everyone? Read more at FastCompany.com.

[VIDEO] Medications Containing Hydrocodone Subject to New, Stricter Prescribing Rules. The Food and Drug Administration has recommended new restrictions on prescription medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the U.S. Click here to learn more.

[Leader’s Choice] This post is recommended by Dr. Michael Lozano, EmCare’s South Division EVP. Questions and Answers on Ebola | Ebola Hemorrhagic Fever via CDC.

[FOR CLINICAL JOB SEEKERS] How to Answer “Tell Me about Yourself” in a Job Interview. Whether you're a clinician or a healthcare professional, here's how to ace one of the most important interview questions.

NEW! Listen to the October podcast from Annals of Emergency Medicine. This podcast covers patient satisfaction, pediatric appendicitis and more. Listen now!

Click here for a handy guide to ACEP 2014.


A Roadmap to Patient Engagement. With patient engagement becoming a central theme in the shifting consumer-driven world of healthcare delivery, providers, payers and patients alike are still in the midst of figuring what, exactly, that means. Read more at MedCityNews.com.


Visit us at these upcoming conferences!


10/11: Anesthesiology 2014 Booth 2136

10/12: ACOEP-The Edge Booth 34

10/16: OTA Annual Meeting

10/27: ACEP 2014 Booth 1611 

11/6: EmCare's Inaugural Cook County Crash Course (C4)

View all upcoming events!

Share    
Comments
Blog post currently doesn't have any comments.